Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
- PMID: 32051133
- DOI: 10.1136/bjophthalmol-2019-315623
Efficacy and safety evaluation of benzalkonium chloride preserved eye-drops compared with alternatively preserved and preservative-free eye-drops in the treatment of glaucoma: a systematic review and meta-analysis
Abstract
Background/aims: This systematic review compared the efficacy and safety of benzalkonium chloride (BAK)-preserved eye-drops with alternatively preserved (AP) and preservative-free (PF) eye-drops.
Methods: PubMed, EMBASE and MEDLINE were searched for randomised controlled trials in June and October 2019. Study selection, data extraction and risk of bias assessment were made by two independent reviewers using the Cochrane Handbook. Studies on prostaglandin analogue or beta-blocker eye-drops and patients with glaucoma or ocular hypertension were included. Primary outcome was change in intraocular pressure (IOP). Secondary outcomes were safety measures as assessed in original study.
Results: Of 433 articles screened, 16 studies were included. IOP meta-analysis was conducted on 13 studies (4201 patients) ranging from 15 days to 6 months. No significant differences between BAK versus PF and AP were identified (95% CI -0.00 to 0.30 mm Hg, p=0.05). Meta-analyses revealed no differences between BAK versus AP and PF with regards to conjunctival hyperaemia (risk ratio (RR) 1.05, 95% CI 0.91 to 1.22, 3800 patients, 9 studies), ocular hyperaemia (RR 1.31, 95% CI 0.96 to 1.78, 2268 patients, 5 studies), total ocular adverse events (RR 1.03, 95% CI 0.88 to 1.20, 1906 patients, 5 studies) or tear break-up time (mean difference 0.89, 95% CI -0.03 to 1.81, 130 patients, 3 studies). Diverse reporting on safety measures made comparison challenging. Risk of bias was assessed as high or unclear in many relevant domains, suggesting potential selective reporting or under-reporting.
Conclusion: No clinically significant differences on efficacy or safety could be determined between BAK versus AP and PF. However, there were substantial uncertainties on safety.PROSPERO registration numberCRD42019139692.
Keywords: drugs; glaucoma; intraocular pressure; ocular surface.
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
Similar articles
-
The use of benzalkonium chloride in topical glaucoma treatment: An investigation of the efficacy and safety of benzalkonium chloride-preserved intraocular pressure-lowering eye drops and their effect on conjunctival goblet cells.Acta Ophthalmol. 2023 Dec;101 Suppl 278:3-21. doi: 10.1111/aos.15808. Acta Ophthalmol. 2023. PMID: 38037546
-
Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of open-angle glaucoma and ocular hypertension: an adjusted Indirect comparison meta-analysis of randomized clinical trials.J Glaucoma. 2014 Jan;23(1):e69-75. doi: 10.1097/IJG.0b013e3182a075e6. J Glaucoma. 2014. PMID: 23881267
-
Objective ocular surface tolerance in patients with glaucoma treated with topical preserved or unpreserved prostaglandin analogues.Eur J Ophthalmol. 2019 Nov;29(6):645-653. doi: 10.1177/1120672118805877. Epub 2018 Oct 10. Eur J Ophthalmol. 2019. PMID: 30301370
-
Noninferiority of Preservative-free Versus BAK-preserved Latanoprost-timolol Fixed Combination Eye Drops in Patients With Open-angle Glaucoma or Ocular Hypertension.J Glaucoma. 2019 Jun;28(6):498-506. doi: 10.1097/IJG.0000000000001248. J Glaucoma. 2019. PMID: 31166287 Clinical Trial.
-
Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study.BMJ Open. 2019 Apr 2;9(4):e024129. doi: 10.1136/bmjopen-2018-024129. BMJ Open. 2019. PMID: 30944129 Free PMC article. Clinical Trial.
Cited by
-
Comparing the tolerability of preservative-free tafluprost versus preserved latanoprost in the management of glaucoma and ocular hypertension - an observer blinded active-control trial.Ir J Med Sci. 2024 Oct;193(5):2589-2595. doi: 10.1007/s11845-024-03704-7. Epub 2024 May 15. Ir J Med Sci. 2024. PMID: 38748195 Clinical Trial.
-
Can the choice of artificial tears harm patients? A narrative review with an overview of the Nordic market.Acta Ophthalmol. 2025 Aug;103(5):586-608. doi: 10.1111/aos.17455. Epub 2025 Feb 8. Acta Ophthalmol. 2025. PMID: 39921541 Free PMC article. Review.
-
Physiochemical Properties and Cytotoxicity of a Benzalkonium Chloride-Free, Micellar Emulsion Ophthalmic Formulation of Latanoprost.Clin Ophthalmol. 2020 Oct 7;14:3057-3064. doi: 10.2147/OPTH.S266453. eCollection 2020. Clin Ophthalmol. 2020. PMID: 33116357 Free PMC article.
-
Tolerability in Glaucoma Patients Switched from Preserved to Preservative-Free Prostaglandin-Timolol Combination: A Prospective Real-Life Study.Clin Ophthalmol. 2022 Sep 28;16:3181-3192. doi: 10.2147/OPTH.S382497. eCollection 2022. Clin Ophthalmol. 2022. PMID: 36196405 Free PMC article. Clinical Trial.
-
Comparison of ocular surface assessment and adherence between preserved and preservative-free latanoprost in glaucoma: a parallel-grouped randomized trial.Sci Rep. 2021 Jul 22;11(1):14971. doi: 10.1038/s41598-021-94574-x. Sci Rep. 2021. PMID: 34294842 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical